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Abstract
Objective: This study validates the off-pump antegrade trans-ventricular route for ultrasound-guided direct access aortic valve replacement.
Direct access aortic valve replacement using a transthoracic and valved stent-based approach offers numerous advantages over the remote
access percutaneous approach and may one day provide an alternative treatment modality for aortic valve disease.Methods: Valved stents were
implanted off-pump in 17 pigs (72.10  8.4 kg) via the direct access transapical approach using a left-sided mini-thoracotomy and continuous
ultrasonic and fluoroscopic guidance. Acute valved stent function was studied with intravascular and two-dimensional intracardiac ultrasound.
The invasive valve gradient was assessed with pull-back pressure catheter. All valved stents were tested in vitro before insertion. Macroscopic
analysis was performed at necropsy. Results: In 11 of the 17 pigs, valved stents were delivered to the target site over the native aortic valve
leaflets without interference of coronary blood flow and with good acute valve function. Three valved stents were deployed supra-annularly, two
of those occluded the right coronary orifice and one the left coronary orifice, leading to fatal outcomes. Three valved stents dislodged into the left
ventricle, one because of size-mismatch and two because of failure to unfold correctly. In 11 properly sized and deployed valved stents, two
showed a moderate and one a severe paravalvular leak. Conclusions: Seventeen pigs underwent direct access valve replacement of the aortic
valve with deployment of a valved stent into the native aorta. Eleven valves observed for an average 5-h period showed satisfactory,
postimplantation valve function.
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Increasing life expectancy and good operative results in
elderly patients undergoing cardiac surgery is expected to
increase the number of heart operations performed annually
in the United States beyond the current rate of 300,000 [1,2].
Arguably the single most important technical innovation in
the history of heart surgery, cardiopulmonary bypass is also a
significant source of risk. The forefront of surgical innovation
is focused on the search for less invasive technologies and
techniques that might one day permit off-pump surgical
therapies, thereby reducing this risk for patients. SurgicalAbbreviations: AcuNav, intracardiac ultrasound; AVR, aortic valve repla-
cement; CBF, coronary blood flow; DAVR, direct access valve replacement;
IVUS, intravascular ultrasound; LAD, left anterior descending; LCA, left cor-
onary artery; LV, left ventricle; PVR, percutaneous valve repalcement; RCSSI,
residual coronary sinus stent index
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doi:10.1016/j.ejcts.2005.12.014aortic valve replacement, the current standard of treatment
for patients with heavily calcified, stenotic aortic valves, is a
good example of a procedure that may benefit from the
convergence of recent developments in interventional
cardiology and minimally invasive, direct access cardiac
surgery.2. Materials and methods
2.1. Valved stent design and in vitro testing
We used a custom-designed valved stent (Fig. 1) based on
a previously described prototype [3,4]. The outer scaffold is
constructed of three linked nitinol Z stents that form a
cylindrical structure with minimal surface coverage. The
device is self-expanding, eliminating the need for balloon
expansion. To complete the device, a low-profile biological
valve is sutured into the stent scaffold. Before implantation
in vivo, all valved stents undergo in vitro static and dynamic
(30 min) performance testing inside a pulsatile hydrodynamic
mock loop circuit, equipped with a high fidelity tip-mounted
C.H. Huber, L.K. von Segesser / European Journal of Cardio-thoracic Surgery 29 (2006) 380—385 381
Fig. 1. The aortic valved stent used for direct access antegrade implantation is
constructed of three linked nitinol Z stents housing a tissue valve.
Fig. 2. Ultrasound-guided intracardiac navigation is achieved through simul-
taneous use intracardiac (AcuNav) and intravascular ultrasound (IVUS). The
AcuNav probe is placed in the right atrium and the IVUS probe is placed through
the left apex into the aortic valve annulus. AcuNav inserted through the R
jugular vein.Millar pressure transducer. Acute valve function is monitored
in vivo with real-time intravascular ultrasound (IVUS)
(12.5 MHz, 6F) (Clearview, Boston Scientific Corporation,
Sunnyvale, CA, USA). Criteria determining suitability for
implantation include transvalvular gradient <8 mmHg and
regurgitation value 18.
2.2. Animal studies
Direct access valved stent implantation was performed in
17 pigs (72.10  8.4 kg). All animals received humane care in
compliance with the ‘Principles of Laboratory Animals’
formulated by the National Society of Medical Research
and the ‘Guide for the Care and Use of Laboratory Animals’
prepared by the Institute of Laboratory Animal resources;
published by the National Institutes of Health (NIH publica-
tion 85-23, revised 1985). All data are expressed as
mean  standard deviation.
2.3. Surgical access
The animals are prepared for surgery by mobilizing the
jugular veins and carotid arteries for complete invasive
monitoring, including insertion of a Swan—Ganz catheter
for continuous cardiac output measurement. An 11-F
introducer (B-Braun, Medical Inc., Bethlehem, PA, USA) is
inserted into the right femoral or the right jugular vein to
provide access for intracardiac ultrasound (AcuNav). A 5—
10 cm left mini-thoracotomy incision is made and access
gained through the sixth intercostal space. A Xylocaine
(1.5 mg/kg) drip is used to minimize arrhythmias. Two
purse-string sutures (Prolene 4-0) are placed on the left
ventricular (LV) apex using the native pericardial sac for
reinforcement. After heparinization (300 IU/kg), the 10-F
AcuNav probe (Sequoia, operating frequencies 4.0—
10.0 MHz, 90 cm insertion length, Acuson Corporation,Mountain View, CA, USA) is inserted into the right atrium
(Fig. 2), permitting visualization and predeployment
measurements of the native aortic valve, root, and
coronary ostia configuration. Obtaining these measure-
ments with the AcuNav probe is superior to TEE, which picks
up postdeployment interference caused by the echo dense
structure of the struts.
2.4. Left ventricular valved stent implantation
At this point in the operation, the animal is prepared to
receive the implant. The implant is hand-crimped to the
delivery device (Fig. 3). The LV apex is punctured with an
over-the-needle catheter and a guide-wire is inserted under
fluoroscopic guidance. An 8-F introducer (Arrows, Reading,
PA, USA) is advanced over the guide-wire, which is passed
through the aortic valve into the descending aorta. Catheter
location is confirmed by AcuNav. The monorail wire-guided
disposable IVUS 6-F catheter transducer (Sonicath Ultra 6,
12.5 MHz Imaging Catheter, Medi-tech, Watertown, MA,
USA) is advanced for aortic road-mapping. The location of
the IVUS probe is monitored with AcuNav and fluoroscopy for
target site identification. Four radiopaque markers are
placed on the skin to provide additional fluoroscopic
reference points (1) at the level of the aortic annulus, (2)
end of the native leaflet in systole, (3) sino-tubular junction,
and (4) beginning of the brachiocephalic trunk. The
fluoroscopic C-arm and operating table are locked into
position to avoid parallaxes.
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Fig. 3. Photo reconstruction of a valved stent delivery system: the valved stent
is collapsed radially and then manually loaded into a standard endoprosthetic
delivery device with a maximum diameter of less than 10 mm in order to
deliver the valved stent into the target location. AcuNav inserted through the R
femoral vein.2.5. Deploying the valved stent
After removing the IVUS and 8-F introducer, the valved
stent delivery system is advanced over the guide-wire under
fluoroscopic and AcuNav guidance (Fig. 3). When fluoroscopic
and sonographic target sites reach congruency, the valved
stent is deployed orthotopically over the native valve leaflets
in two steps. The distal end is released first. Then, if the
device position remains stable, the proximal end is released.
The valved stent is initially targeted to land slightly above the
target site, to permit fine adjustments in positioning. The
device can be pulled back slightly, but it cannot be advanced
into position. In this way, after opening the first row of Z
stents, the whole device can be pulled back until the target
site lines up fluoroscopically and sonographically.
The self-expanding nitinol stent has a low metal-to-stent
ratio with minimal contact area between the interface of the
stent and aortic wall. These features increase the expansion
force at the interface, creating a firm attachment to the
aortic root, without injuring the aortic wall. This stent design
has been successfully used for thoracic aortic endovascular
and endoluminal aortic valve procedures [3,5].
2.6. The residual coronary sinus stent index (RCSSI)
We used the residual coronary sinus stent index to
evaluate CBF impairment. The RCSSI is a comparison between
the coronary cross-sectional surface area and the plane
defined by the valved stent and the native aortic wall. This
index compares the flow ratio between the native coronary
flow with the blood flow that passes through the valved stent
after implantation. Measurements required to calculate the
index include (a) the coronary diameter, which is measured at
the termination of the sinus portion, and (b) the residual
stent aortic wall plane, which is measured at the level of the
coronary orifice. All measurements are obtained with
intracardiac ultrasound. To calculate the index value, the
distance of the stent from the aortic wall (residual gap at the
level of the aortic sinus portion) is divided by the coronarydiameter [3]. No CBF impairment was observed in this series
for index values >1.
2.7. Outcome assessment
All valved stents were monitored in vivo to assess leaflet
motion, planimetric valve orifice, RCSSI, CBF, characteristics
of the left coronary artery (LCA), transvalvular gradient,
regurgitation, and paravalvular leak. All animals were
sacrificed at the conclusion of the experiment and macro-
scopic analysis was performed at necropsy.3. Results
3.1. In vitro study
Before implantation, all of the valved stents demon-
strated good valvular function with a pressure gradient of
5.5  2.1 mmHg at mean pulsatile flow rate of 4.5  1.8 L/
min. IVUS imaging exhibited full opening and closing of the
pericardial leaflets in all valved stents.
3.2. In vivo study
Eleven of the 17 valved stents implanted in 17 pigs
(72.10  8.4 kg) were delivered accurately into the pre-
defined target location without any evidence of CBF
impairment. Three valved stents were deployed too high,
into a supra-annular position and two of those obstructed the
right coronary artery and the third valved stent occluded the
orifice of the left main coronary artery. All animals died as
direct consequence of impaired CBF.
Two valved stents were incorrectly sized (too small) which
caused them to dislodge into the left ventricle after they
were initially appropriately placed. Another valved stent
failed to unfold correctly and slipped back into the left
ventricle.
Measurements from intracardiac and intravascular ultra-
sound showed good valve function in all 11 valved stents with
low transvalvular gradient of less than 6 mmHg. On invasive
measurement transvalvular gradient was 5.5  2.7 mmHg
and 5.8  3.4 mmHg in two-dimensional intracardiac mea-
surements. The overall planimetric valve orifice area was
equally good at 2.9  1.3 cm2. There was complete leaflet
excursion and competent closing in all 11 correctly deployed
and sized valved stents. Of these, two had a mild-to-
moderate and one a moderate-to-severe paravalvular leak.
Continuous cardiac output remained stable 5.6  1.0 L/
min (preimplantation) versus 4.2  0.7 L/min (postdeploy-
ment) for the 11 correctly delivered valved stents.
Intracardiac color Doppler imaging revealed laminar blood
flow.
The procedure time was typically 2 h, and device delivery
and deployment time was between 4 and 6 min. No signs of
coronary flow impairment were observed in 11 of the 17
valved stents.
The RCSSI was obtained to evaluate possible flow
impairment in the left coronary artery. Absence of inter-
ference with coronary blood flow was confirmed by RCSSI
index, which was >1 in all 11 correctly positioned and
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confirmed the position and safe anchoring of the device to
the aortic wall in 11 of the 17 valved stents. None of the
stents showed signs of coronary obstruction. Necropsy
confirmed the above-described results. Macroscopic analysis
provided no evidence of damage to the aortic wall and no sign
of dissection or hematoma. All valved stents were free of
thrombus and structural damage.Fig. 4. Anatomical relationship illustrating the straight-line approach of the
direct access implantation technique through a mini-thoracotomy and via the
left ventricular apex. DAVR decreases the working distance to ‘surgical
dimensions,’ permitting the surgeon to work in close proximity to the aortic
target.4. Discussion
Surgical valve repair or replacement is the current
treatment of choice for stenotic or insufficient valve
pathologies. Yet, surgical valve repair or replacement
typically requires the use of extracorporeal cardiopulmonary
bypass, which is associated with known risks and limitations.
The convergence of new techniques in interventional
cardiology with minimally invasive cardiac surgery techni-
ques has given rise to several potential new therapies,
including percutaneous valve replacement (PVR) [6—9]. The
PVR movement began with Anderson et al. [10], in 1992, who
performed the first remote access transcatheter implant of
an expandable aortic valve in closed chest pigs. That same
year, Pavcnik et al. [11] published his experimental
evaluation of an integrated valved stent implanted via
remote access. Sochman et al. [12] followed suit in 2002,
performing a feasibility study of percutaneous transcatheter
aortic disc valve implantation via remote access. Also in
2002, Bonhoeffer et al. [13] performed the first successful
human percutaneous implantation of a pulmonary valved
stent in a pulmonary artery conduit via remote access.
Finally, Cribier et al. [14] conducted the first clinical remote
access percutaneous implantation of a valved stent into a
heavily calcified aortic valve.
4.1. Limitations of remote access PVR
Obstacles remain before PVR can be safely used in
humans for the treatment of aortic valve disease. Fish [15]
has recently published a summary of these limitations. First
and foremost, the complication profile is high for the
insertion of large introducer systems such as would be
needed to navigate through and work on diseased valves.
These include local complications such as vessel rupture,
dissection, pseudoaneurysm formation, bleeding, vessel
stenosis, and thrombus. PVR also creates new complica-
tions associated with traversing implements and devices
through a long vascular path to reach the desired target in
the heart. These include increased risk of kinking, higher
shear stress on the vessel wall, and a demanding and
cumbersome delivery process that hinders the precise
delivery of the implantation device. Small vessel diameter
also limits the size of the delivery device, making removal
of diseased valves nearly impossible. Some of the potential
problems of using PVR for aortic valve disease were
demonstrated by Cribier et al. [16] in 2004. Cribier et al.
[16] used a transseptal approach and reported significant
complications in end-stage inoperable patients with
calcified aortic stenosis. One-third of patients developed
severe mitral incompetence, from injury caused by passingthe guide-wire through the mitral valve and in a substantial
part of patient the valved stent showed severe paravalvular
leakage.
4.2. Direct access valve replacement (DAVR)
The direct access valve replacement technique [17,18] we
propose has the potential of eliminating many of the
disadvantages of remote access PVR. This technique
represents a true convergence of the interventional and
standard surgical approach and has the potential to be
applied to the most severe forms of aortic valve disease.
DAVR involves the percutaneous transmyocardial entry of any
cardiac cavity, with preference for the (a) ventricular apex in
aortic or pulmonary valve procedures and (b) atrial wall in
mitral or tricuspid procedures [19]. Essential to this
technique is the simultaneous use of intravascular and
intracardiac ultrasound. These instruments are used to
measure and identify the coronary anatomy, monitor stent
delivery and deployment, and assess postimplantation
coronary blood flow, unhampered by artifact from the highly
echodense Z struts of the implantation device, a significant
drawback of using transesophageal echocardiography (TEE).
Other advantages of DAVR include the straight line access to
the target site (Fig. 4), which improves handling and permits
insertion of long handled decalcification tools, increased
caliber delivery systems, and simultaneous use of other
interventional tools, such as embolic projection devices or
temporary ventricular support pumps.
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remote access PVR described above, while preserving and
potentially improving upon the low patient morbidity and
mortality rates associated with cardiac surgery. The cap-
ability of using embolic filters, temporary valve-tipped
catheters, or short-term axial ventricular assist devices
could, in future, elevate DAVR to the position of therapy of
choice for patients with valvular cardiomyopathy and other
selected conditions.
4.3. Intracardiac ultrasound for adequate visualization
Good outcome with DAVR depends on adequate visualiza-
tion of the target area and precise monitoring of valved stent
delivery. Our good results with IVUS used for endovascular
aneurysm repair [20] prompted us to extend this technique
into endoluminal cardiac procedures. To this, we added
intracardiac ultrasound (AcuNav), which permitted enhanced
visualization despite the echodense stent structures, which
interfered with TEE (Fig. 2). AcuNav also permitted
postimplantation flow monitoring. Finally, AcuNav supported
three-dimensional assessment, helping us tomonitor delivery
of valved stent on target. Routine use of IVUS and AcuNav
ultrasound guidance provides real-time out of the lumen
dimensions and identification of the coronary configuration.
Together the above elements overcome many of the short-
comings of the remote access approach.5. Conclusion
This novel technique to implement surgical aortic valve
replacement off-pump while promising, is premature;
surgical aortic valve repair/replacement remains the stan-
dard of care. Maneuvering through the complex aortic root
configuration generates a need for technology more sophis-
ticated than is currently available, for example, a self-
orienting valved stent that can be safely anchored to the
aortic wall without injuring the aortic annulus. The necessity
of removing a highly calcified, stenotic aortic valve will
require specialized tools, temporary ventricular support, and
embolic protection devices. However, DAVR may ultimately
be the best approach to the aortic and mitral valve [21]. In
comparison to remote access techniques, DAVR decreases the
working distance to ‘surgical dimensions,’ permitting the
surgeon to work in close proximity to the aortic target
(Fig. 4). Direct access through the left ventricular apex also
permits simultaneous insertion of valve decalcification and
removal tools, embolic protection, and ventricular assist
devices, as well as larger delivery systems.
As life expectancy increases and cardiac valve procedures
improve, more and more elderly patients will require new or
outlive old valve operations justifying reoperation for
replacement or re-repair. Particularly in this age group,
efforts to reduce the stress of surgery through the use of
minimally invasive procedures and development of off-pump
surgical techniques are paramount. Nevertheless, in the
setting of redo-aortic valve surgery any percutaneous
intervention is facing one major challenge—the risk of
patient-prosthesis mismatch in particular in patients with a
previous small prosthetic valve. In order to avoid a mismatchsituation the prosthetic valve would need to be removed
first. None of the percutaneous techniques has addressed the
problem of removing a prosthetic heart valve yet, but the
transapical direct access valve replacement approach is
certainly the most promising in order to provide the
necessary access and tools for this undertaken.
Furthermore, the design of the valved stent might need to
be modified in order to allow for increased effective orifice
area by using parts of the former prosthetic valve as
additional structural elements. And finally, the venue of the
percutaneous techniques as new therapeutic options for
heart valve disease might lead to design modifications or new
designs of the standard biological or even mechanical
prosthetic heart valve in order to permit a later percutaneous
intervention.
More research will be needed before DAVR can be safely
and successfully applied in humans, but the results of our
current animal studies [17,18] support the feasibility of this
approach. It behooves the cardiac valve surgeon to support
and explore surgical innovations based on developments in
DAVR and PVR, advancing the art and science of minimally
invasive cardiac techniques.
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Appendix A. Conference discussion
Dr M. Antunes (Coimbra, Portugal): Do you think that with this we will be
in a position to compete with our fellow cardiologists, because they have gone
first and appear to be a bit more advanced? But this appears to be to me far
more precise than the methods that they are using. What is your current
thinking about that?
Dr Huber: I think there are obvious advantages of being a cardiac surgeon:
you have direct visualization, you know the anatomy much better, you
understand the valve function, you know the disease. If you look at the
cardiologists, obviously they have very good experience as well and they have
had very good results, very early results. But if you think about the first US
clinical trial the antegrade percutaneous approach, that soon after its start
was discontinued by the FDA or themedical device company, it very much looks
like that using notmature techniques too early might set you up for drawbacks.
Maybe cardiac surgeons are a little bit more conservative and try to aim on the
safe side, but they are certainly very innovative. Seeing the amount of interestin novel techniques and the strong presence at the techno college shows, I
think, that we are moving in the right direction, and we certainly will not stay
behind the cardiologists.
Dr T. David (Toronto, Canada): What measures do you take to prevent the
valve from tilting when you deliver it? In other words, unless you can deploy the
valve absolutely perpendicular to the level of the annulus, which in the humans
it is frequently not perpendicular to the outflow tract because the noncoronary
sinus and annulus tend to be lower than the other two, the deployed valve
would be slightly tilted.
You didn’t show us any specimen of the aortic cusps against the coronary
orifices. It troubles me that if one deploys a valve in the presence of normal
cusps, they may obstruct the coronary arteries, at least partially.
Dr Huber: Answering your first question, well, the delivery device is at a
very early stage of development and it is pretty hard to very precisely keep the
perpendicular level to the aortic outflow tract or the aortic valve, but the
intravascular ultrasound gives very good visualization of the target zone and
certainly helps the monitoring of the deployment.
Regarding your second question, we presented our concept at the EACTS in
2003. We were concerned about the native leaflets staying in place while the
new valved stent was delivered into the aortic root about potential obstruction
of the coronaries.
But looking at postmortem specimens as well as ultrasonic images, we
realized that actually when the valved stent is deployed into the aortic root,
the native leaflets will get spread and stretched out around the valved stent, so
therefore will stay away from the native aortic wall because they are attached
at two points, and stretching these two points will make the leaflets come
centerwise, rapping around the stent structure. Furthermore, the presence of
the natural sinuses in front of the coronaries are natural distance-keepers
between the valved stent and the native aortic wall if you don’t oversize the
valved stent too much. Therefore, we came up with the residual coronary sinus
stent index (RCSSI). We hypothesized that if the distance from the stent to the
aortic wall is at least as big or bigger as the native coronary orifice, the cross-
sectional area of this surface here will allow or permit enough flow through the
coronaries to not impair coronary flow.
The only time we really experienced ischemia was while the valved stent
was deployed too high, and the annular part that anchors the valve in the stent
unfortunately positioned itself in front of the coronary orifice. Therefore,
certainly all measures need to be taken to be make sure that the annular part
of the valved stent is delivered precisely in the aortic annulus and anchored
there very safely.
